Peter A. Thompson, who serves as a director of Sionna Therapeutics, Inc. (NASDAQ: SION), completed the sale of common stock amounting to approximately $2,472,342 in two trades executed in mid-April. The transactions were reported on a Form 4 filed with the Securities and Exchange Commission and carried out under a pre-arranged 10b5-1 trading plan.
The filing shows that on April 17, 2026, 52,397 shares were sold at $44.68 per share. The following day, April 18, 2026, an additional 2,948 shares changed hands at $44.52 each. Together, these disposals equal 55,345 shares sold at prices ranging from $44.52 to $44.68.
At the time of reporting, Sionna Therapeutics stock is trading at $41.79, which is below the prices at which Mr. Thompson’s reported sales occurred. The stock has, however, experienced significant appreciation over the past year, gaining roughly 250% on a 12-month basis.
The shares sold are held indirectly by OrbiMed Private Investments VIII, LP, identified in the Form 4 as the reporting entity. Mr. Thompson is a member of OrbiMed Advisors LLC, which plays a role in managing OPI VIII. In the filing he disclaims beneficial ownership of the securities except to the extent of any pecuniary interest. After the April trades, the indirect holdings attributed to Mr. Thompson’s reporting entity total 2,964,774 shares of Sionna Therapeutics common stock.
Independent valuation commentary referenced in the filing notes that InvestingPro’s Fair Value estimates indicate the stock appears overvalued at current levels given the company’s market capitalization of $1.92 billion and reported negative earnings of $1.88 per share.
Analyst coverage has been active recently. Guggenheim raised its price target on Sionna Therapeutics to $50 and reiterated a Buy rating. Separately, Citizens initiated coverage with a Market Outperform rating and set a $63 price target, the firm said it arrived at this figure using a risk-adjusted discounted cash flow model.
On the corporate fundamentals front, Sionna Therapeutics reported $310.3 million in cash at the end of fiscal 2025 and has guided that these cash reserves are expected to last through 2028. Operationally, the company is advancing a Phase IIa study, named preciSION, which seeks to demonstrate a measurable improvement in cystic fibrosis patients who carry specified genetic markers.
Context and implications
These insider sales, executed through a 10b5-1 plan, coincide with analyst optimism on valuation targets and a company-funded multi-year runway for clinical development. The filings and analyst notes underline continued focus on the company’s cystic fibrosis program and liquidity position.